The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
Portfolio Pulse from Benzinga Insights
Recent analysis of Regeneron Pharmaceuticals (NASDAQ:REGN) by 10 experts shows a mix of bullish to bearish sentiments, with a shift towards more positive ratings in the last 30 days. The average 12-month price target for REGN has increased by 5.22% to $1036.8. Analysts have adjusted their ratings and price targets based on Regeneron's performance and market conditions. The company, known for its products in eye disease, cardiovascular disease, cancer, and inflammation, shows a positive revenue trend but below-average net margin, ROE, and ROA, indicating potential profitability and efficiency challenges.
February 27, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has seen a positive shift in analyst sentiment, with an increased average 12-month price target. Despite this, the company faces challenges in profitability and efficiency.
The increase in the average 12-month price target and the shift towards more positive analyst ratings suggest a short-term positive impact on REGN's stock price. However, the underlying concerns about profitability and efficiency metrics could temper long-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100